In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma
Felix Korell,Nelson H. Knudsen,Tamina Kienka,Giulia Escobar,Celeste Nobrega,Seth Anderson,Andrew Y. Cheng,Maria Zschummel,Amanda Bouffard,Michael C. Kann,Sadie Goncalves,Hans W. Pope,Mitra Pezeshki,Alexander Rojas,Juliette S.M.T. Suermondt,Merle Phillips,Trisha R. Berger,Sangwoo Park,Diego Salas-Benito,Elijah P. Darnell,Filippo Birocchi,Mark B. Leick,Rebecca C. Larson,John G. Doench,Debettama Sen,Kathleen B. Yates,Robert T. Manguso,Marcela V. Maus
DOI: https://doi.org/10.1101/2024.11.19.624352
2024-11-19
Abstract:Chimeric antigen receptor (CAR) T cells are highly effective in hematologic malignancies. However, loss of CAR T cells can contribute to relapse in a significant number of patients. These limitations could potentially be overcome by targeted gene editing to increase CAR T cell persistence. Here, we performed in vivo loss-of-function CRISPR screens in BCMA-targeting CAR T cells to investigate genes that influence CAR T cell persistence, function and efficacy in a human multiple myeloma model. We tracked the expansion and persistence of CRISPR-library edited T cells in vitro and then at early and late timepoints in vivo to track the performance of gene modified CAR T cells from manufacturing to survival in tumors. The screens revealed several context-specific regulators of CAR T cell expansion and persistence. Ablation of RASA2 and SOCS1 enhanced T cell expansion in vitro, while loss of PTPN2, ZC3H12A, and RC3H1 conferred early selective growth advantages to CAR T cells in vivo. Strikingly, we identified cyclin-dependent kinase inhibitor 1B (CDKN1B), a cell cycle regulator, as the most important factor limiting CAR T cell fitness at late timepoints in vivo. CDKN1B ablation increased BCMA CAR T cell proliferation and effector function in response to antigen, significantly enhancing tumor clearance and overall survival. Thus, our findings reveal differing effects of gene-perturbation on CAR T cells over time and in different selective environments, highlight CDKN1B as a promising target to generate highly effective CAR T cells for multiple myeloma, and underscore the importance of in vivo screening as a tool for identifying genes to enhance CAR T cell function and efficacy.
Biology